Skip to content

Warenkorb

Der Warenkorb ist leer.

Gesamt (exkl. MwSt.) £0,00
Warenkorb überprüfen & bezahlen
Proteine und Peptide

Human Mdm2 p53 Binding Protein Homolog (MDM2), Active Protein

Produktgrößen
50 ug
£412,00
RPU54979-50UG
100 ug
£537,00
RPU54979-100UG
1 mg
£2128,00
RPU54979-1MG
Über dieses Produkt
SKU:
RPU54979
Zusätzliche Namen:
hdm2|HDMX|Mouse Double Minute 2,Human Homolog Of p53-Binding Protein|Oncoprotein Mdm2
Anwendung:
Detection/Quantitation, Tissue Culture
Buffer:
Freeze-dried powder|PBS, pH7.4, containing 0.01% SKL, 5% Trehalose.
CE/IVD:
RUO
Weitere Details:
Human Mdm2 p53 Binding Protein Homolog (MDM2), Active Protein is a purified Prokaryotic Protein.
Formulierung:
Freeze-dried powder
Immunogen:
Mdm2 p53 Binding Protein Homolog (MDM2)
Molekulargewicht:
44kda
Physischer Zustand:
freeze-dried
Reinheit:
>95%
Versandbedingungen:
Blue Ice
Lagerbedingungen:
-20[o]C Avoid freeze/thaw cycles.
Hersteller:
Biomatik
Typ:
Proteins, Peptides, Small Molecules & Other Biomolecules: Recombinant Proteins
Catalog Protein.JPG
Mouse double minute 2 homolog (MDM2) also known as E3 ubiquitin-protein ligase Mdm2 is a cellular oncoprotein that recognizes the N-terminal trans-activation domain (TAD) of the p53 tumor suppressor and as an inhibitor of p53 transcriptional activation. The human homologue of this protein is sometimes called Hdm2. The p53 tumor suppressor is the key target of MDM2. It has been identified as a p53 interacting protein that represses p53 transcriptional activity and also acts as an E3 ubiquitin ligase, targeting both itself and p53 for degradation by the proteasome. MDM2 is capable of auto-polyubiquitination, and in complex with p300, a cooperating E3 ubiquitin ligase, is capable of polyubiquitinating p53. Besides, S100 Calcium Binding Protein (S100) has been identified as an interactor of MDM2, thus a binding ELISA assay was conducted to detect the interaction of recombinant human MDM2 and recombinant human S100. Briefly, MDM2 were diluted serially in PBS, with 0.01% BSA (pH 7.4). Duplicate samples of 100uL were then transferred to S100-coated microtiter wells and incubated for 2h at 37°C. Wells were washed with PBST and incubated for 1h with anti-MDM2 pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody, wells were aspirated and washed 3 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37°C. Finally, add 50uL stop solution to the wells and read at 450nm immediately. The binding activity of of MDM2 and S100 was shown in Figure 1, and this effect was in a dose dependent manner.
Figure 2. SDS-PAGE